Key result
Musculoskeletal involvement is a common manifestation of systemic lupus erythematosus that can be classified into nondeforming nonerosive arthritis, Jaccoud's arthropathy, and rhupus, requiring tailored therapeutic approaches.
Why the study?
Identifying the pathogenetic mechanisms underlying musculoskeletal manifestations in SLE is crucial to develop therapeutic strategies to suppress synovial inflammation, prevent deformities, and improve quality of life.
This symposium summary discusses the pathogenetic mechanisms and therapeutic approaches for musculoskeletal manifestations of systemic lupus erythematosus.
SLE arthritis subtyping via biomarkers/MRI may refine future trials; leaves open any impact on current management.
Musculoskeletal involvement is one of the most common manifestations of systemic lupus erythematosus (SLE), with a negative impact on both quality of life and overall prognosis. SLE arthritis can be classified into three different subtypes, with different prevalence and characteristic biomarkers and MRI findings. Identifying the pathogenetic mechanisms underlying musculoskeletal manifestations' development is crucial to develop therapeutic strategies to suppress synovial inflammation, prevent erosions and deformities, and improve SLE patients' quality of life. Hence, here we discuss the main pathogenetic mechanisms and therapeutic approaches of musculoskeletal manifestations of SLE from the 2022 International GISEA/OEG Symposium.
No takes yet. Share an insight, caveat, or question.
Ceccarelli et al. (2022) conducted a review in Systemic Lupus Erythematosus (SLE) arthritis. Musculoskeletal involvement is a common manifestation of systemic lupus erythematosus that can be classified into nondeforming nonerosive arthritis, Jaccoud's arthropathy, and rhupus, requiring tailored therapeutic approaches.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: